He established the Long Term Transplant Clinic at Vanderbilt in 2006, which allows for systematic multidisciplinary follow up of patients after
allogeneic stem cell transplant.
• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % •
Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study
An allogeneic stem cell transplant is a complex procedure and can result in some issues.
Of these 34 patients, 13 (38 %) have remained in remission for five years, and an additional two patients whose disease did not progress after BV went on to achieve remission after receiving
allogeneic stem cell transplant (in which healthy stem cells are taken from a donor and administered to the patient).
«It thus appears quite possible that these selective agonists will be administered in the future to patients who are candidates for
allogeneic stem cell transplants.
Our expertise includes both autologous and
allogeneic stem cell transplants (using cells directly from the patient and from another person, respectively), using cells derived from bone marrow, peripheral blood and cord blood.
Not exact matches
CLL is the most prevalent leukemia in adults and it is not considered curable without an
allogeneic (donor)
stem cell transplant.
The only documented long - term complete remissions reported in multiple myeloma patients have occurred with
allogeneic bone marrow transplantation, where a donor's blood
stem cells (graft) are
transplanted into the patient (host) with multiple myeloma.
In the future, outpatient blood and bone marrow
stem cell transplantation will be offered to a broader group of patients with other blood disorders and for
allogeneic transplants (
transplant from non-twin donor
stem cells).
Patients receive one of two types of
stem cell - based
transplants: autologous, in which a patient donates and receives back his / her own
stem cells; or
allogeneic, in which bone marrow - derived
stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.
Ponatinib Extends Survival Over
Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European Bone Marrow
Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.
If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo
stem cell transplantation (each
allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).
Thus, one can
transplant fully
allogeneic hematopoietic
stem cells and co-
transplant, for example, hearts from the hematopoietic
stem cell donor to induce lifelong donor - specific acceptance of the
transplant, without deleterious immunosuppression [4].
Allogeneic transplants: Patients receive
stem cells from a person other than an identical twin.